AUA 2024: Prostate Cancer: Dissemination and Availability of Minimally Invasive Treatments to Underserved Populations
AUA 2024 availability of minimally invasive treatments for prostate cancer (PCa), minimally invasive surgery,
AUA 2024 availability of minimally invasive treatments for prostate cancer (PCa), minimally invasive surgery,
Massimo (Max) Loda discusses his team’s research on the role of the microenvironment in prostate cancer progression, published in Nature Communications. The study focuses on…
InPACT trial, penile cancer, Squamous Cell Cancer of the Penis, Radiotherapy in the Management of Squamous Cell Cancer of the Penis, InPact trial, ECOG-ACRIN, GOG…
By prioritizing continuous patient engagement and strategic communication across the entire care journey, healthcare organizations can drive real progress toward value-based care.
An early-stage clinical trial of a radiopharmaceutical drug developed by J&J showed some signs of efficacy in prostate cancer patients, but four participants in the…
Andrea Miyahira hosts Ping Mu to discuss his group’s research on prostate cancer resistance to anti-androgens. Dr. Mu’s study, published in Oncogene, focuses on the…
Our editors will be attending ENDO 2024 in Boston, MA, June 1–4 and would love to meet with you to discuss your research. Get in…
One of the most significant sites for such commemoration is Arlington National Cemetery, the final resting place for U.S. military personnel of every major American…
The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and…
Fadi Fakhouri, MD, PhD, disuccess the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.
prostate cancer, Prostate specific membrane antigen (PSMA), positron emission tomography (PET), PSMA PET, PSMA-radioguided surgery (PSMA-RGS), PSMA-Radioguided Surgery in Recurrent Prostate Cancer, Robot-Assisted and Open…